The ability of natural and synthetic cannabinoids (CBs) to inhibit cell growth and to induce apoptosis in several cancer cell lines is well documented. Nevertheless, the role of classical cannabinoid receptors CB1 and CB2 in many cases appeared insignificant in determining drug response, while other targets have been implicated. Regarding cutaneous melanoma, only few studies have been reported, and the involvement of CB1/CB2 receptors or other CB targets needs further investigations.
Aim of this study was to investigate the CB compounds effects on cell viability (using A375, human skin melanoma cancer cell line) in order to clarify whether CBs may represent a new therapeutic strategy in this type of cancer.
Our results indicated a melanoma cell growth inhibition induced by CBs. The most interesting result was obtained by AM251, in spite of its antagonist profile on CB1 receptor, and AEA, CB1 selective agonist
